The race to create a SARS-CoV-2 vaccine is on
As the the novel corona virus outbreak rages on in South Korea, Iran and Italy researchers and pharmaceutical companies have entered a race to get a vaccine ready in a try to shift the odds in the favor of humanity.
Moderna Therapeutics, a biotech company in Massachusets, US, shipped the first batches of a vaccine that was created in just 42 days, following the SARS-CoV-2 genome was released by chinese scientists in January. The vaccine is now being prepared to enter human trials as early as April, as reported by Time magazine.
But Moderna is not the only ones in the race. A research group in Israel, Galilee Research Institute (MIGAL), claims that a vaccine will be ready in three weeks, and available for treatment with 90 days. This after discovering the poultry corona virus is very similar to corona virus that infect humans, and that a modified poultry vaccine is thought to be effective also against SARS-CoV-2.
Forced development of vaccines is not without dangers in itself, as the failed swine-flu mass vaccination in Sweden showed, with serious long-term side effects. However, the seriousness of the COVID-19 disease may motivate a greater risk taking in prevention and treatment efforts.
I will keep following and reporting on the efforts of developing a vaccine for the current outbreak.